(HealthDay)—Key challenges have been identified for health professionals communicating the role of human papillomavirus (HPV) in oropharyngeal squamous cell cancer (OSCC), according to a study published online Oct. 28 in ...
Oct 31, 2014
0
0
A study to determine whether vaccines, particularly those for hepatitis B (HepB) and human papillomavirus (HPV), increased the risk of multiple sclerosis (MS) or other acquired central nervous system demyelinating syndromes ...
Oct 20, 2014
0
0
A high alcohol intake is linked to a heightened risk of human papillomavirus infection among men, suggests research in the journal Sexually Transmitted Infections. The findings seem to be independent of other risk factors ...
Oct 2, 2014
1
0
(HealthDay)—An experimental vaccine meant to protect against nine types of human papillomavirus (HPV) could prevent 90 percent of all cervical cancers, a new study suggests.
Oct 1, 2014
0
0
(Medical Xpress)—New research led by King's College London suggests that many women under 30 with cervical cancer are diagnosed more than 3 months after first having symptoms. In many cases this was because they did not ...
Sep 29, 2014
0
0
A new study shows that patients with human papillomavirus (HPV) – the same virus associated with both cervical and head and neck cancer – positive oropharyngeal cancer see significantly higher rates of complete response ...
Sep 17, 2014
0
0
Human papillomavirus (HPV) is one of the most common sexually transmitted infections. Up to 80% of sexually active women are infected at some point in their lives and infection with specific "high risk" strains of HPV has ...
Sep 16, 2014
0
0
(HealthDay)—Neither parents' nor adolescents' knowledge about human papillomavirus (HPV) vaccines predicts vaccination compliance, according to a study published online Sept. 15 in Pediatrics.
Sep 16, 2014
0
0
A human papillomavirus (HPV) vaccine used in Australia has reduced the prevalence of vaccine-targeted and non-targeted HPV types, researchers have found.
Sep 16, 2014
1
0
The Food and Drug Administration has approved Genentech's Avastin for a new use against late-stage cervical cancer, the sixth indication for the blockbuster biotech drug.
Aug 15, 2014
0
0
